Acceptability of 'as needed' biologic therapy in psoriasis: insights from a multi-stakeholder mixed methods study.
David GleesonManeeha NaveedLucy MoorheadHelen McAteerGeorgia SewellArlene McGuireJohn WeinmanJonathan N W N BarkerKatherine JonesSarah C E ChapmanCatherine H SmithSatveer K MahilPublished in: The British journal of dermatology (2024)
These data indicate that 'as needed' biologic therapy in psoriasis is acceptable for both patients and clinicians. Formal assessment of clinical effectiveness and cost effectiveness is warranted, to enable the real-world potential of this approach to be realised.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- randomized controlled trial
- systematic review
- prognostic factors
- peritoneal dialysis
- palliative care
- clinical trial
- electronic health record
- big data
- machine learning
- risk assessment
- climate change
- atopic dermatitis
- mesenchymal stem cells
- bone marrow
- deep learning